... . The tumor characteristics that predict clinical benefit from erlotinib after progression on a cetuximab-containing regimen is yet to be elucidated, but that is an area Dr. Borghaei would like to ...
... whose tumors harbored wild-type KRAS were found to have a higher survival advantage when treated with cetuximab in a randomized trial by the National Cancer Institute of Canada Clinical Trials Group. ...
... cancer because the disease progresses so quickly.
The study also found that patients who received the addition of cetuximab were 48% more likely to experience tumour shrinkage.
"Fewer than 30% of ...
... 4 head and neck cancer were treated initially with a combination of docetaxel, cisplatin and cetuximab, after which they received radiation therapy and additional cisplatin and cetuximab. Cetuximab, ...
... out-of-control growth circuits in cancer cells
Some of the new therapies, such as erlotinib and cetuximab, work against the signals that come from epidermal growth factor receptor (EGFR), which ...
... the Dutch Colorectal Cancer Group) with chemotherapy plus bevacizumab, with or without the addition of cetuximab. In each patient they measured levels of circulating tumor cells before treatment, and ...
Gene marker indicates doubling of survival time in advanced colorectal cancer treated with cetuximab. A study shows value of circulating tumor cells in patients on targeted therapy.
... value of this drug in this disease."
Chemotherapy, radiotherapy and cetuximab in head and neck cancer
Treating locally ... 2-3, 5-6 and 8-10. Cetuximab was also added weekly. "Both complete response ...
... FOLFOX (leucovorin, fluorouracil and oxaliplatin) chemotherapy, or newer, targeted drugs such as cetuximab and bevacizumab could be added."
At present, the test for the 11-gene signature takes about ...
... patients with a mutation in the BRAF gene do not respond to anti-EGFR therapy with cetuximab and panitumumab. The finding could help doctors better identify which patients are likely to benefit from ...
... .
This study, the first reported study of these two targeted therapies (bevacizumab and cetuximab) with chemotherapy (carboplatin and paclitaxel), combined the four drugs as first-line therapy in ...
... downstream and see where the two pathways converge."
Various EGFR inhibitors, such as erlotinib and cetuximab, have been approved by the FDA to treat head and neck cancer, lung cancer, colon cancer ...
... the disease. The investigators focused on the use of the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux) because of these drugs' clinical importance, significant media coverage, and ...
... selectively against specific key molecules of tumor cells. Among these is an antibody called cetuximab, which attaches to a protein molecule that is found in large amounts on the surface of many types ...
... this cutting tool, called u-PAR, might be an indicator of therapy effectiveness in non-small cell lung cancer: the more u-PAR tumor cells produce, the less the anti-cancer drug cetuximab is effective.
